nach oben

Endocrine

Erschienen in:

01.10.2012 | Review

Testosterone and heart failure

verfasst von: Maurizio Volterrani, Giuseppe Rosano, Ferdinando Iellamo

Erschienen in: Endocrine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Testosterone deficiency is a generalized phenomenon seen in the course of chronic heart failure (CHF). Reduction in circulating testosterone level is a predictor of deterioration of functional capacity over time, underscoring the role of testosterone deficiency in CHF. Anabolic hormones are determinants of exercise capacity and circulating levels of anabolic hormones strongly determine muscle mass and strength. Testosterone deficiency is involved in the pathophysiology of CHF, contributing to some features of this syndrome, such as the reduced muscle mass, abnormal energy handling, fatigue, dyspnea and, finally, cachexia. This review summarizes current knowledge on the role of testosterone deficiency in the pathophysiology of CHF, gaining insights from the potential implications of testosterone as supplementation therapy.

S.D. Anker, T.P. Chua, P. Ponikowski et al., Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96, 526–534 (1997)PubMedCrossRef

Y. Moriyama, H. Yasue, M. Yoshimura et al., The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. J. Clin. Endocrinol. Metab. 85, 1834–1840 (2000)PubMedCrossRef

P.E. Kontoleon, M.I. Anastasiou-Nana, P.D. Papapetrou et al., Hormonal profile in patients with congestive heart failure. Int. J. Cardiol. 87, 179–183 (2003)PubMedCrossRef

P.J. Pugh, R.D. Jones, J.N. West, T.H. Jones, K.S. Channer, Testosterone treatment for men with chronic heart failure. Heart 90, 446–447 (2004)PubMedCrossRef

C.J. Malkin, T.H. Jones, K.S. Channer, Testosterone in chronic heart failure. Front. Horm. Res. 37, 183–196 (2009)PubMedCrossRef

S.D. Anker, A.L. Clark, M. Kemp, C. Salsbury, M.M. Teixeira, P.G. Hellewell, A.J. Coats, Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J. Am. Coll. Cardiol. 30, 997–1001 (1997)PubMedCrossRef

E.A. Jankowska, B. Biel, J. Majda et al., Anabolic deficiency in men with chronic heart failure prevalence and detrimental impact on survival. Circulation 114, 1829–1837 (2006)PubMedCrossRef

E.A. Jankowska, G. Gerasimos Filippatos, B. Ponikowska et al., Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. J. Cardiac Fail. 15, 442–450 (2009)CrossRef

N. Pitteloud, V.K. Mootha, A.A. Dwyer et al., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28, 1636–1642 (2005)PubMedCrossRef

10.

M. Izquierdo, K. Hakkinen, A. Anton et al., Maximal strength and power, endurance performance, and serum hormones in middle-aged and elderly men. Med. Sci. Sports Exerc. 33, 1577–1587 (2001)PubMedCrossRef

11.

Z.R. Haydar, M.R. Blackman, J.D. Tobin, J.G. Wright, J.L. Fleg, The relationship between aerobic exercise capacity and circulating IGF1 levels in healthy men and women. J. Am. Geriatr. Soc. 48, 139–145 (2000)PubMed

12.

F. Hartgens, H. Kuipers, J.A. Wijnen, H.A. Keizer, Body composition, cardiovascular risk factors and liver function in long-term androgenic–anabolic steroids using body builders three months after drug withdrawal. Int. J. Sports Med. 17, 429–433 (1996)PubMedCrossRef

13.

I. Sinha-Hikim, J. Artaza, L. Woodhouse et al., Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. 283, 154–164 (2002)

14.

T.W. Storer, L. Magliano, L. Woodhouse et al., Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J. Clin. Endocrinol. Metab. 88, 1478–1485 (2003)PubMedCrossRef

15.

R. Wolfe, A. Ferrando, M. Sheffield-Moore, R. Urban, Testosterone and muscle protein metabolism. Mayo Clin. Proc. 75(Suppl), S55–S60 (2000)PubMed

16.

A.A. Ferrando, M. Sheffield-Moore, C.W. Yeckel et al., Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am. J. Physiol. Endocrinol. Metab. 282, E601–E607 (2002)PubMed

17.

F. Kadi, Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. Br. J. Pharmacol. 154, 522–528 (2008)PubMedCrossRef

18.

R. Hambrecht, E. Fiehn, J. Yu et al., Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J. Am. Coll. Cardiol. 29, 1067–1073 (1997)PubMedCrossRef

19.

A.J. Coats, A.L. Clark, M. Piepoli, M. Volterrani, P.A. Poole-Wilson, Symptoms and quality of life in heart failure: the muscle hypothesis. Br. Heart J. 72, S36–S39 (1994)PubMedCrossRef

20.

M.F. Piepoli, A. Kaczmarek, D.P. Francis et al., Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 114, 126–134 (2006)PubMedCrossRef

21.

M. Piepoli, A.L. Clark, M. Volterrani, S. Adamopoulos, P. Sleight, A.J. Coats, Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 93, 940–952 (1996)PubMedCrossRef

22.

F. Iellamo, J.A. Sala-Mercado, M. Ichinose et al., Spontaneous baroreflex control of heart rate during exercise and muscle metaboreflex activation in heart failure. Am. J. Physiol. Heart Circ. Physiol. 293, H1929–H1936 (2007)PubMedCrossRef

23.

S.D. Anker, P. Ponikowski, S. Varney et al., Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349, 1050–1053 (1997)PubMedCrossRef

24.

P.P. Ponikowski, T.P. Chua, D.P. Francis et al., Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 104, 2324–2330 (2001)PubMedCrossRef

25.

M.F. Piepoli, A.C. Scott, A. Capucci, A.J. Coats, Skeletal muscle training in chronic heart failure. Acta Physiol. Scand. 171, 295–303 (2001)PubMedCrossRef

26.

G. Caminiti, M. Volterrani, F. Iellamo et al., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J. Am. Coll. Cardiol. 54, 919–927 (2009)PubMedCrossRef

27.

M. Czesla, G. Mehlhorn, D. Fritzsche, G. Asmussen, Cardiomyoplasty-improvement of muscle fibre type transformation by anabolic steroid. J. Mol. Cell Cardiol. 29, 2989–2996 (1997)PubMedCrossRef

28.

I. Ustünel, G. Akkoyunlu, R. Demir, The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: a histochemical, morphometric and ultrastructural study. Anat. Histol. Embryol. 32, 70–79 (2003)PubMedCrossRef

29.

C.J. Malkin, P.J. Pugh, J.N. West, E.J.R. Van Beek, T.H. Jones, K.S. Channer, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur. Heart J. 27, 57–64 (2006)PubMedCrossRef

30.

A.M. Traish, F. Saad, R.J. Feeley, A. Guay, The dark side of testosterone review deficiency: III: cardiovascular disease. J. Androl. 30, 477–494 (2009)PubMedCrossRef

31.

T. Montalcini, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone, A. Pujia, Endogenous testosterone and endothelial function in postmenopausal women. Coron. Artery Dis. 18, 9–13 (2007)PubMedCrossRef

32.

K. Saltiki, G. Papageorgiou, P. Voidonikola et al., Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels. Endocrine 37, 329–335 (2010)PubMedCrossRef

33.

P.J. Pugh, T.H. Jones, K.S. Channer, Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur. Heart J. 24, 909–915 (2003)PubMedCrossRef

34.

K. Swedberg, J. Cleland, H. Dargie et al., Guidelines on the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Heart J. 26, 1115–1140 (2005)PubMedCrossRef

35.

J.L. Fleg, I.L. Pina, G.J. Balady et al., Assessment of functional capacity in clinical and research applications. An advisory from the Committee on Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 102, 1591–1597 (2000)PubMedCrossRef

36.

D. Francis, W. Shamin, L.C. Davies et al., Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO₂ slope and peak VO₂. Eur. Heart J. 21, 154–161 (2000)PubMedCrossRef

37.

R. Arena, J. Myers, J. Abella, Development of a ventilatory classification system in patients with heart failure. Circulation 115, 2410–2417 (2007)PubMedCrossRef

38.

R. Martin-Du Pan, Androgen deficiency in women: indications and risks of treatment with testosterone or DHEA. Rev. Med. Suisse 3, 792–796 (2007)PubMed

39.

T. Montalcini, V. Migliaccio, Y. Ferro, C. Gazzaruso, A. Pujia, Androgens for postmenopausal women’s health? Endocrine (2012). doi:10.1007/s12020-012-9692-1

40.

K. Miller, B. Biller, C. Beauregard et al., Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683–1690 (2006)PubMedCrossRef

41.

K.K. Miller, B.M.K. Biller, A. Schaub et al., Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J. Clin. Endocrinol. Metab. 92, 2474–2479 (2007)PubMedCrossRef

42.

F. Iellamo, M. Volterrani, G. Caminiti et al., Testosterone therapy in women with chronic heart failure: a pilot double-blind randomized placebo controlled study. J. Am. Coll. Cardiol. 56, 1310–1316 (2010)PubMedCrossRef

43.

J. Shifren, G. Braunstein, J. Simon et al., Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343, 682–688 (2000)PubMedCrossRef

44.

G. Wittert, I. Chapman, M. Haren, S. Mackintosh, P. Coates, J. Morley, Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Biol Sci Med Sci 58, 618–625 (2003)CrossRef

45.

C.J. Malkin, T.H. Jones, K.S. Channer, The effect of testosterone on insulin sensitivity in men with heart failure. Eur. J. Heart Fail. 9, 44–50 (2007)PubMedCrossRef

46.

S. von Haehling, W. Doehner, S.D. Anker, Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc. Res. 73, 298–309 (2007)CrossRef

47.

J.W. Swan, S.D. Anker, C. Walton et al., Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 30, 527–532 (1997)PubMedCrossRef

48.

E. Ingelsson, J. Sundstrom, J. Amlov, B. Zethelius, L. Lind, Insulin resistance and risk of congestive heart failure. JAMA 294, 334–341 (2005)PubMedCrossRef

49.

N. Suskin, R.S. McKelvie, R.J. Burns et al., Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur. Heart J. 21, 1368–1375 (2000)PubMedCrossRef

50.

W. Doehner, D. Gathercole, M. Cicoira et al., Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. Int. J. Cardiol. 138, 19–24 (2010)PubMedCrossRef

51.

A. Holmäng, P. Björntorp, The effects of testosterone on insulin sensitivity in male rats. Acta Physiol. Scand. 146, 505–510 (1992)PubMedCrossRef

52.

D. Kapoor, E. Goodwin, K.S. Channer, T.H. Jones, Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocr. 154, 899–906 (2006)CrossRef

53.

A. Mortara, M.T. La Rovere, G.D. Pinna et al., Arterial baroreflex modulation of heart rate in chronic heart failure. Clinical and hemodynamic correlates and prognostic implications. Circulation 96, 3450–3458 (1997)PubMedCrossRef

54.

R.B. Simerly, C. Chang, M. Muramatsu, L.W. Swanson, Distribution of androgen and estrogen mRNA-containing cells in the rat brain: an in situ hybridization study. J. Comp. Neurol. 294, 76–95 (1990)PubMedCrossRef

55.

G.R. Ward, A.A. Abdel-Rahman, Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats. BMC Pharmacol. 6, 2 (2006)PubMedCrossRef

56.

F. Altamirano, C. Oyarce, P. Silva et al., Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J. Endocrinol. 202, 299–307 (2009)PubMedCrossRef

57.

T. Papamitsou, D. Barlaggiannis, V. Papaliagkas, E. Kotadinou, M. Dermentzopoulou-Theodoridou, Testosterone-induced hypertrophy, fibrosis and apoptosis of cardiac cells: an ultrastructural and immunohistochemical study. Med. Sci. Monit. 17, 266–273 (2011)

Titel: Testosterone and heart failure
verfasst von: Maurizio Volterrani
Giuseppe Rosano
Ferdinando Iellamo
Publikationsdatum: 01.10.2012
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2012
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9725-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Testosterone and heart failure

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Ectopic posterior pituitary causing hyperprolactinemia

BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness

The effects of fever on hormone ghrelins, immunoglobulins, and heat shock protein 70 expression after swine flu vaccinations

Effects of prolonged exercise on agouti-related protein: a pilot study

Effects of habitual diet on ethnic differences in serum total ghrelin

Biomechanical properties of the mid-shaft femur in middle-aged hypophysectomized rats as assessed by bending test

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin